MICROBIX BIOSYSTEMS INC (MBX.CA) Stock Fundamental Analysis
Canada - TSX:MBX - CA59501P1045 - Common Stock
0.25 CAD
0 (0%)
MBX gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 22 industry peers in the Biotechnology industry. MBX scores excellent on profitability, but there are some minor concerns on its financial health. MBX is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! This makes MBX very considerable for growth investing!
1. Profitability
1.1 Basic Checks
MBX had negative earnings in the past year.
In the past year MBX had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: MBX reported negative net income in multiple years.
Of the past 5 years MBX 4 years had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -0.85%, MBX belongs to the top of the industry, outperforming 95.24% of the companies in the same industry.
The Return On Equity of MBX (-1.11%) is better than 95.24% of its industry peers.
MBX has a better Return On Invested Capital (1.38%) than 95.24% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.85% | ||
| ROE | -1.11% | ||
| ROIC | 1.38% |
ROA(3y)4.84%
ROA(5y)-2.84%
ROE(3y)6.48%
ROE(5y)-11.45%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
In the last couple of years the Profit Margin of MBX has grown nicely.
With an excellent Operating Margin value of 3.26%, MBX belongs to the best of the industry, outperforming 95.24% of the companies in the same industry.
MBX's Operating Margin has improved in the last couple of years.
With an excellent Gross Margin value of 55.77%, MBX belongs to the best of the industry, outperforming 95.24% of the companies in the same industry.
MBX's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 3.26% | ||
| PM (TTM) | N/A | ||
| GM | 55.77% |
OM growth 3Y-14.86%
OM growth 5Y15.81%
PM growth 3Y-7.25%
PM growth 5Y128.26%
GM growth 3Y0.68%
GM growth 5Y4.41%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), MBX is destroying value.
MBX has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, MBX has more shares outstanding
MBX has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 2.38 indicates that MBX is not a great score, but indicates only limited risk for bankruptcy at the moment.
MBX has a better Altman-Z score (2.38) than 85.71% of its industry peers.
MBX has a Debt/Equity ratio of 0.21. This is a healthy value indicating a solid balance between debt and equity.
MBX has a Debt to Equity ratio of 0.21. This is in the better half of the industry: MBX outperforms 61.90% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.38 |
ROIC/WACC0.18
WACC7.54%
2.3 Liquidity
A Current Ratio of 9.73 indicates that MBX has no problem at all paying its short term obligations.
MBX has a better Current ratio (9.73) than 95.24% of its industry peers.
A Quick Ratio of 6.15 indicates that MBX has no problem at all paying its short term obligations.
MBX has a better Quick ratio (6.15) than 90.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.73 | ||
| Quick Ratio | 6.15 |
3. Growth
3.1 Past
The earnings per share for MBX have decreased strongly by -106.48% in the last year.
The Earnings Per Share has been growing by 8.58% on average over the past years. This is quite good.
MBX shows a decrease in Revenue. In the last year, the revenue decreased by -9.53%.
Measured over the past years, MBX shows a quite strong growth in Revenue. The Revenue has been growing by 13.62% on average per year.
EPS 1Y (TTM)-106.48%
EPS 3Y8.58%
EPS 5YN/A
EPS Q2Q%-750%
Revenue 1Y (TTM)-9.53%
Revenue growth 3Y10.96%
Revenue growth 5Y13.62%
Sales Q2Q%-31.37%
3.2 Future
MBX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 51.83% yearly.
Based on estimates for the next years, MBX will show a very strong growth in Revenue. The Revenue will grow by 21.86% on average per year.
EPS Next Y50%
EPS Next 2Y41.42%
EPS Next 3Y51.83%
EPS Next 5YN/A
Revenue Next Year7.14%
Revenue Next 2Y20.68%
Revenue Next 3Y21.86%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
MBX is valuated cheaply with a Price/Forward Earnings ratio of 6.19.
100.00% of the companies in the same industry are more expensive than MBX, based on the Price/Forward Earnings ratio.
MBX is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.55, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 6.19 |
4.2 Price Multiples
MBX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. MBX is cheaper than 100.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 12.18 |
4.3 Compensation for Growth
MBX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
MBX has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as MBX's earnings are expected to grow with 51.83% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.42%
EPS Next 3Y51.83%
5. Dividend
5.1 Amount
No dividends for MBX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:MBX (10/31/2025, 7:00:00 PM)
0.25
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners0.43%
Inst Owner ChangeN/A
Ins Owners14.73%
Ins Owner ChangeN/A
Market Cap34.88M
Revenue(TTM)21.14M
Net Income(TTM)-324800
Analysts80
Price Target0.92 (268%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 6.19 | ||
| P/S | 1.65 | ||
| P/FCF | N/A | ||
| P/OCF | 57.96 | ||
| P/B | 1.19 | ||
| P/tB | 1.37 | ||
| EV/EBITDA | 12.18 |
EPS(TTM)0
EYN/A
EPS(NY)0.04
Fwd EY16.16%
FCF(TTM)0
FCFYN/A
OCF(TTM)0
OCFY1.73%
SpS0.15
BVpS0.21
TBVpS0.18
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.85% | ||
| ROE | -1.11% | ||
| ROCE | 1.92% | ||
| ROIC | 1.38% | ||
| ROICexc | 2.09% | ||
| ROICexgc | 2.5% | ||
| OM | 3.26% | ||
| PM (TTM) | N/A | ||
| GM | 55.77% | ||
| FCFM | N/A |
ROA(3y)4.84%
ROA(5y)-2.84%
ROE(3y)6.48%
ROE(5y)-11.45%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y-16.73%
ROICexgc growth 5Y20.32%
ROICexc growth 3Y-19.11%
ROICexc growth 5Y24.01%
OM growth 3Y-14.86%
OM growth 5Y15.81%
PM growth 3Y-7.25%
PM growth 5Y128.26%
GM growth 3Y0.68%
GM growth 5Y4.41%
F-Score3
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 2.59 | ||
| Cap/Depr | 51.1% | ||
| Cap/Sales | 4.13% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 25.12% | ||
| Profit Quality | N/A | ||
| Current Ratio | 9.73 | ||
| Quick Ratio | 6.15 | ||
| Altman-Z | 2.38 |
F-Score3
WACC7.54%
ROIC/WACC0.18
Cap/Depr(3y)133.78%
Cap/Depr(5y)133.99%
Cap/Sales(3y)8.11%
Cap/Sales(5y)7.74%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-106.48%
EPS 3Y8.58%
EPS 5YN/A
EPS Q2Q%-750%
EPS Next Y50%
EPS Next 2Y41.42%
EPS Next 3Y51.83%
EPS Next 5YN/A
Revenue 1Y (TTM)-9.53%
Revenue growth 3Y10.96%
Revenue growth 5Y13.62%
Sales Q2Q%-31.37%
Revenue Next Year7.14%
Revenue Next 2Y20.68%
Revenue Next 3Y21.86%
Revenue Next 5YN/A
EBIT growth 1Y-68.79%
EBIT growth 3Y-5.54%
EBIT growth 5Y31.58%
EBIT Next Year-29.47%
EBIT Next 3Y21.52%
EBIT Next 5YN/A
FCF growth 1Y83.08%
FCF growth 3Y41.04%
FCF growth 5YN/A
OCF growth 1Y17.98%
OCF growth 3Y27.25%
OCF growth 5Y155.41%
MICROBIX BIOSYSTEMS INC / MBX.CA FAQ
What is the ChartMill fundamental rating of MICROBIX BIOSYSTEMS INC (MBX.CA) stock?
ChartMill assigns a fundamental rating of 6 / 10 to MBX.CA.
Can you provide the valuation status for MICROBIX BIOSYSTEMS INC?
ChartMill assigns a valuation rating of 6 / 10 to MICROBIX BIOSYSTEMS INC (MBX.CA). This can be considered as Fairly Valued.
What is the profitability of MBX stock?
MICROBIX BIOSYSTEMS INC (MBX.CA) has a profitability rating of 7 / 10.
What is the earnings growth outlook for MICROBIX BIOSYSTEMS INC?
The Earnings per Share (EPS) of MICROBIX BIOSYSTEMS INC (MBX.CA) is expected to grow by 50% in the next year.